Sign In
Buy NUMIF
$0.0308
-0.0014 (-4.35%)
At Close: Jul 31, 2026
Numinus Wellness Inc.'s (NUMIF) CEO Payton Nyquvest on Q3 2022 Results - Earnings Call Transcript
11:43pm, Thursday, 14'th Jul 2022
Numinus Wellness Inc. (OTCQX:NUMIF) Q3 2022 Earnings Conference Call July 14, 2022 5:30 PM ET Company Participants Jamie Kokoska - Vice President, Investor Relations Payton Nyquvest - Founder and CEO
Numinus Wellness sees fiscal 3Q revenue rise by 31.8% thanks to new acquisitions Mindspace and the Neurology Centre of Toronto
05:05pm, Thursday, 14'th Jul 2022
Numinus Wellness Inc posted fiscal third-quarter results that saw its revenue jump 31.8% year-over-year, helped immeasurably by the company's new acquisitions Mindspace and the Neurology Centre of Tor
Numinus Wellness piloting program to offer ketamine-assisted psychotherapy as a health benefit for eligible employees
10:01am, Thursday, 23'rd Jun 2022
Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) announced it has launched a pilot program in Utah that offers ketamine-assisted psychotherapy as a health benefit for eligible employees. The company's clin
Numinus Wellness completes acquisition of Novamind; announces executive team expansion
07:27am, Monday, 13'th Jun 2022
Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has completed the acquisition of Novamind Inc (CSE:NM) following the latter's receipt of a final order from the British Columbia Supreme Court. Numi
Numinus Wellness says shareholders have approved resolution in connection with the proposed acquisition of Novamind
06:41am, Thursday, 09'th Jun 2022
Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) announced that shareholders have approved the company's resolution to issue common shares in the company in connection with the proposed acquisition of Nova
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) announced that it has been granted approval from Health Canada to carry out psychedelic-assisted therapy using psilocybin to treat an applicant with treat
Numinus Wellness announces concert series exploring role of music in psychedelic-assisted therapy
09:23am, Friday, 29'th Apr 2022
Numinus Wellness Inc has announced a new series of ceremonial concerts that will explore the role music plays in psychedelic-assisted therapy. According to the company, the Music as Medicine by Numinu
Numinus Wellness sees fiscal 2Q revenue soar by 240% thanks to its robust wellness clinic acquisitions
09:57am, Monday, 18'th Apr 2022
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) posted second-quarter fiscal year 2022 financial results that saw its revenue jump 240% year-over-year, driven primarily by its robust acquisitions in th
Numinus Wellness Inc. (NUMIF) CEO Payton Nyquvest on Q2 2022 Results - Earnings Call Transcript
09:49pm, Thursday, 14'th Apr 2022
Numinus Wellness Inc. ( OTCPK:NUMIF ) Q2 2022 Results Conference Call April 14, 2022 5:30 PM ET Company Participants Jamie Kokoska - VP, IR Payton Nyquvest - Founder and CEO John Fong - CFO Evan Wood
Numinus Wellness strikes deal to acquire US psychedelic healthcare company Novamind for C$26.2M
09:57am, Tuesday, 12'th Apr 2022
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) said it is expanding its presence in the US with the acquisition of Novamind, which owns a network of mental health clinics and research sites, in an all
Numinus to Participate in Upcoming Investor Conferences in April 2022
07:30am, Thursday, 07'th Apr 2022
VANCOUVER, BC , April 7, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evide
Numinus Wellness completes first MDMA administration in PTSD trial sponsored by MAPS
08:33am, Wednesday, 30'th Mar 2022
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) said it has advanced to the next implementation phase in a key post-traumatic stress disorder (PTSD) clinical trial by enrolling and dosing the first cli
Numinus Wellness says its research lab receives new biosecurity license for expansion
12:09pm, Monday, 14'th Mar 2022
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) announced that its research lab, Numinus Bioscience, has been approved by the Public Health Agency of Canada for a containment level 2 (CL2) pathogens and
Psychedelics Co. Numinus Wellness Appoints New Bioscience Advisors To Bolster IP Development
09:21am, Tuesday, 01'st Feb 2022
Psychedelics-focused company Numinus Wellness Inc. NUMI NUMIF announced the appointment of three key advisors to its new Bioscience Advisory Board. The Vancouver-based company appointed Graham Pecheni
Numinus Wellness welcomes three key advisors to its new bioscience advisory board
09:15am, Tuesday, 01'st Feb 2022
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) has appointed three key advisors –Graham Pechenik, Paul Spagnuolo, and Cory Harris–to its new bioscience advisory board. The new bioscience advisory
